Gritstone bio Q4 2023 Earnings Report

Gritstone bio EPS Results

• Actual EPS: -$0.26
• Consensus EPS: -$0.36
• Beat/Miss: Beat by +$0.10
• One Year Ago EPS: N/A

Gritstone bio Revenue Results

• Actual Revenue: $10.38 million
• Expected Revenue: $4.80 million
• Beat/Miss: Beat by +$5.58 million
• YoY Revenue Growth: N/A

Gritstone bio Announcement Details

• Quarter: Q4 2023
• Date: 3/5/2024
• Time: N/A

Gritstone bio (NASDAQ:GRTS), a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.